Is it recommended for patients with advanced lung cancer to take platinib?

Platinib is a targeted therapy for RET gene fusions or mutations. In non-small cell lung cancer (NSCLC), although RET fusion mutations are relatively rare, with an incidence rate of about 1%~2%, such patients often respond poorly to traditional chemotherapy and multi-kinase inhibitors. The emergence of platinib provides a new treatment option for these patients. Especially for patients with RET fusion-positive NSCLC who have received platinum-containing chemotherapy and whose disease has progressed, platinib has shown significant efficacy.

According to the results of multiple clinical studies, platinib has shown impressive efficacy in the treatment of RETfusion-positive NSCLC. For example, in the ARROW study, the median survival (OS) of previously treated patients reached 44.3 months, while the median OS of treatment-naïve patients has not yet been reached, indicating that platinib can bring durable survival benefits to patients. At the same time, the safety of platinib has also been widely recognized. Its adverse reaction spectrum is similar to other TKI drugs, which are mainly hematological reactions, and there are no serious side effects such as obvious cardiotoxicity.

Based on the above analysis, platinib is a treatment option worth considering for patients with advanced lung cancer and RET fusion mutations. However, before using platinib, patients should first undergo genetic testing to confirm the presence of RET fusions or mutations. In addition, because platinib may cause some adverse reactions, such as hypertension, interstitial lung disease, etc., the patient's physical condition needs to be closely monitored during use and the treatment plan should be adjusted in a timely manner according to the doctor's recommendations.